Pfizer's berobenatide shows up to 10.2% weight loss and 2.2% blood sugar reduction in Phase 2b trial in patients with obesity and type 2 diabetes.
The long-acting GLP-1 shot that was the centerpiece of Pfizer’s acquisition of Metsera last year looks effective in patients with both obesity and diabetes, according …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes
Pfizer's monthly obesity shot, berobenatide, shows similar side effects to Wegovy, aiming for differentiation in the weight-loss…
The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs…
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could…
Roche says it has one obesity drug with a potential best-in-class safety profile, and another with a similar shot at leading in…
Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2…
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
